Changes in bone markers in children with asthma during inhaled budesonide and nedocromil treatments

• Published in: Acta pædiatrica (Oslo) Vol. 85; no. 10; p. 1176
• Main Authors: Sorva, R, Tähtelä, R, Turpeinen, M, Juntunen-Backman, K, Haahtela, T, Risteli, L, Risteli, J, Sorva, A
• Format: Journal Article
• Language: English
• Published: Norway 01.10.1996
• Subjects: Anti-Asthmatic Agents - pharmacology; Anti-Asthmatic Agents - therapeutic use; Asthma - drug therapy; Asthma - metabolism; Biomarkers - analysis; Body Height; Body Weight; Bone Remodeling - drug effects; Budesonide; Child; Collagen - metabolism; Female; Humans; Male; Nedocromil - pharmacology; Nedocromil - therapeutic use; Peptide Fragments - analysis; Pregnenediones - pharmacology; Pregnenediones - therapeutic use; Procollagen - analysis; Respiratory Function Tests; Treatment Outcome
• ISSN: 0803-5253
• DOI: 10.1111/j.1651-2227.1996.tb18224.x

We evaluated serum and urinary markers of bone turnover in 14 children with asthma during inhaled budesonide and nedocromil treatments. Both the markers of formation (serum carboxy- and amino-terminal propeptides of type I procollagen and serum osteocalcin) and the markers of degradation (serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links) decreased (p < 0.05) during budesonide treatment for 6 months. During inhaled nedocromil treatment (for the following 6 months), the markers returned to the normal levels. These transient decreases in the markers of both formation and degradation of bone suggest that inhaled budesonide may slightly decrease the bone turnover rate. However, normal "coupling" between formation and degradation seemed to operate, e.g. a change in one resulted in a corresponding change in the other, so that net bone loss did not necessarily occur.